Prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) 8473T>C polymorphism associated with prognosis for patients with colorectal cancer treated with capecitabine and oxaliplatin

Jong Gwang Kim; Yee Soo Chae; Sang Kyun Sohn; Joon Ho Moon; Hun Mo Ryoo; Sung Hwa Bae; Yoon Seop Kum; Seong Woo Jeon; Kyoung Hoon Lim; Byung Mo Kang; In Ja Park; Gyu Seog Choi; Soo Han Jun

doi:10.1007/s00280-009-0947-3

Prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) 8473T>C polymorphism associated with prognosis for patients with colorectal cancer treated with capecitabine and oxaliplatin

Jong Gwang Kim, Yee Soo Chae, Sang Kyun Sohn, Joon Ho Moon, Hun Mo Ryoo, Sung Hwa Bae, Yoon Seop Kum, Seong Woo Jeon, Kyoung Hoon Lim, Byung Mo Kang, In Ja Park, Gyu Seog Choi, Soo Han Jun

Research output: Contribution to journal › Article › peer-review

24 Scopus citations

Abstract

Purpose: The present study analyzed the polymorphisms of apoptosis-related genes and their impact on the response to chemotherapy and survival of patients with colorectal cancer. Patients and methods: A total of 76 patients with recurrent or metastatic colorectal cancer treated with capecitabine and oxaliplatin (XELOX) combination chemotherapy were enrolled in the present study. The single nucleotide polymorphisms of 15 apoptosis-related genes (TP53, BCL2L, TNFRSF10B, AKT1, PTGS2/COX2, BID, RIPK1, FAS, FASL, caspase 3, and caspase 6-10) were determined using a PCR-RFLP assay. Results: No significant association between the polymorphisms and the response was found for any of the genes analyzed. However, the T/T genotype of PTGS2 8473T>C (rs5275) was significantly correlated with a better progression-free survival (PFS) and overall survival (OS) when compared to the combined T/C and C/C genotype (Hazard ratio [HR] = 0.47; P value = 0.046 and HR = 0.16; P = 0.013, respectively) in a multivariate analysis adjusted for age, sex, performance status, disease status and curative resection. No association was noted between the other polymorphisms and survival. Conclusion: The PTGS2 8473T>C polymorphism was found to be correlated with PFS and OS in patients with advanced colorectal cancer treated with XELOX chemotherapy.

Original language	English
Pages (from-to)	953-960
Number of pages	8
Journal	Cancer Chemotherapy and Pharmacology
Volume	64
Issue number	5
DOIs	https://doi.org/10.1007/s00280-009-0947-3
State	Published - Oct 2009

Keywords

Biomarker
Chemotherapy
Colorectal cancer
PTGS2
Polymorphism

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00280-009-0947-3

Cite this

Kim, J. G., Chae, Y. S., Sohn, S. K., Moon, J. H., Ryoo, H. M., Bae, S. H., Kum, Y. S., Jeon, S. W., Lim, K. H., Kang, B. M., Park, I. J., Choi, G. S., & Jun, S. H. (2009). Prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) 8473T>C polymorphism associated with prognosis for patients with colorectal cancer treated with capecitabine and oxaliplatin. Cancer Chemotherapy and Pharmacology, 64(5), 953-960. https://doi.org/10.1007/s00280-009-0947-3

@article{f2aac8ef9c0e4d87b3f14d0144c5fd30,

title = "Prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) 8473T>C polymorphism associated with prognosis for patients with colorectal cancer treated with capecitabine and oxaliplatin",

abstract = "Purpose: The present study analyzed the polymorphisms of apoptosis-related genes and their impact on the response to chemotherapy and survival of patients with colorectal cancer. Patients and methods: A total of 76 patients with recurrent or metastatic colorectal cancer treated with capecitabine and oxaliplatin (XELOX) combination chemotherapy were enrolled in the present study. The single nucleotide polymorphisms of 15 apoptosis-related genes (TP53, BCL2L, TNFRSF10B, AKT1, PTGS2/COX2, BID, RIPK1, FAS, FASL, caspase 3, and caspase 6-10) were determined using a PCR-RFLP assay. Results: No significant association between the polymorphisms and the response was found for any of the genes analyzed. However, the T/T genotype of PTGS2 8473T>C (rs5275) was significantly correlated with a better progression-free survival (PFS) and overall survival (OS) when compared to the combined T/C and C/C genotype (Hazard ratio [HR] = 0.47; P value = 0.046 and HR = 0.16; P = 0.013, respectively) in a multivariate analysis adjusted for age, sex, performance status, disease status and curative resection. No association was noted between the other polymorphisms and survival. Conclusion: The PTGS2 8473T>C polymorphism was found to be correlated with PFS and OS in patients with advanced colorectal cancer treated with XELOX chemotherapy.",

keywords = "Biomarker, Chemotherapy, Colorectal cancer, PTGS2, Polymorphism",

author = "Kim, {Jong Gwang} and Chae, {Yee Soo} and Sohn, {Sang Kyun} and Moon, {Joon Ho} and Ryoo, {Hun Mo} and Bae, {Sung Hwa} and Kum, {Yoon Seop} and Jeon, {Seong Woo} and Lim, {Kyoung Hoon} and Kang, {Byung Mo} and Park, {In Ja} and Choi, {Gyu Seog} and Jun, {Soo Han}",

year = "2009",

month = oct,

doi = "10.1007/s00280-009-0947-3",

language = "English",

volume = "64",

pages = "953--960",

journal = "Cancer Chemotherapy and Pharmacology",

issn = "0344-5704",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "5",

}

Kim, JG, Chae, YS, Sohn, SK, Moon, JH, Ryoo, HM, Bae, SH, Kum, YS, Jeon, SW , Lim, KH, Kang, BM, Park, IJ, Choi, GS & Jun, SH 2009, 'Prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) 8473T>C polymorphism associated with prognosis for patients with colorectal cancer treated with capecitabine and oxaliplatin', Cancer Chemotherapy and Pharmacology, vol. 64, no. 5, pp. 953-960. https://doi.org/10.1007/s00280-009-0947-3

Prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) 8473T>C polymorphism associated with prognosis for patients with colorectal cancer treated with capecitabine and oxaliplatin. / Kim, Jong Gwang; Chae, Yee Soo; Sohn, Sang Kyun et al.
In: Cancer Chemotherapy and Pharmacology, Vol. 64, No. 5, 10.2009, p. 953-960.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) 8473T>C polymorphism associated with prognosis for patients with colorectal cancer treated with capecitabine and oxaliplatin

AU - Kim, Jong Gwang

AU - Chae, Yee Soo

AU - Sohn, Sang Kyun

AU - Moon, Joon Ho

AU - Ryoo, Hun Mo

AU - Bae, Sung Hwa

AU - Kum, Yoon Seop

AU - Jeon, Seong Woo

AU - Lim, Kyoung Hoon

AU - Kang, Byung Mo

AU - Park, In Ja

AU - Choi, Gyu Seog

AU - Jun, Soo Han

PY - 2009/10

Y1 - 2009/10

N2 - Purpose: The present study analyzed the polymorphisms of apoptosis-related genes and their impact on the response to chemotherapy and survival of patients with colorectal cancer. Patients and methods: A total of 76 patients with recurrent or metastatic colorectal cancer treated with capecitabine and oxaliplatin (XELOX) combination chemotherapy were enrolled in the present study. The single nucleotide polymorphisms of 15 apoptosis-related genes (TP53, BCL2L, TNFRSF10B, AKT1, PTGS2/COX2, BID, RIPK1, FAS, FASL, caspase 3, and caspase 6-10) were determined using a PCR-RFLP assay. Results: No significant association between the polymorphisms and the response was found for any of the genes analyzed. However, the T/T genotype of PTGS2 8473T>C (rs5275) was significantly correlated with a better progression-free survival (PFS) and overall survival (OS) when compared to the combined T/C and C/C genotype (Hazard ratio [HR] = 0.47; P value = 0.046 and HR = 0.16; P = 0.013, respectively) in a multivariate analysis adjusted for age, sex, performance status, disease status and curative resection. No association was noted between the other polymorphisms and survival. Conclusion: The PTGS2 8473T>C polymorphism was found to be correlated with PFS and OS in patients with advanced colorectal cancer treated with XELOX chemotherapy.

AB - Purpose: The present study analyzed the polymorphisms of apoptosis-related genes and their impact on the response to chemotherapy and survival of patients with colorectal cancer. Patients and methods: A total of 76 patients with recurrent or metastatic colorectal cancer treated with capecitabine and oxaliplatin (XELOX) combination chemotherapy were enrolled in the present study. The single nucleotide polymorphisms of 15 apoptosis-related genes (TP53, BCL2L, TNFRSF10B, AKT1, PTGS2/COX2, BID, RIPK1, FAS, FASL, caspase 3, and caspase 6-10) were determined using a PCR-RFLP assay. Results: No significant association between the polymorphisms and the response was found for any of the genes analyzed. However, the T/T genotype of PTGS2 8473T>C (rs5275) was significantly correlated with a better progression-free survival (PFS) and overall survival (OS) when compared to the combined T/C and C/C genotype (Hazard ratio [HR] = 0.47; P value = 0.046 and HR = 0.16; P = 0.013, respectively) in a multivariate analysis adjusted for age, sex, performance status, disease status and curative resection. No association was noted between the other polymorphisms and survival. Conclusion: The PTGS2 8473T>C polymorphism was found to be correlated with PFS and OS in patients with advanced colorectal cancer treated with XELOX chemotherapy.

KW - Biomarker

KW - Chemotherapy

KW - Colorectal cancer

KW - PTGS2

KW - Polymorphism

UR - http://www.scopus.com/inward/record.url?scp=69049117222&partnerID=8YFLogxK

U2 - 10.1007/s00280-009-0947-3

DO - 10.1007/s00280-009-0947-3

M3 - Article

C2 - 19219602

AN - SCOPUS:69049117222

SN - 0344-5704

VL - 64

SP - 953

EP - 960

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

IS - 5

ER -

Prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) 8473T>C polymorphism associated with prognosis for patients with colorectal cancer treated with capecitabine and oxaliplatin

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this